18F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer-Reference-Cited by-同舟云学术

18F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer

Published:2013-10 Issue:5 Volume:6 Page:586-IN7
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Lheureux Stéphanie,Lecerf Charlotte,Briand Mélanie,Louis Marie-Hélène,Dutoit Soizic,Jebahi Abdelghani,Giffard Florence,Fournier Cécile Blanc,Batalla Alain,Poulain Laurent,Aide Nicolas

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group;Miller;J Clin Oncol,2009

3. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer;Aletti;Am J Obstet Gynecol,2007

4. Relapsed ovarian cancer: challenges and management strategies for a chronic disease;Armstrong;Oncologist,2002

5. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan;Gordon;J Clin Oncol,2001

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One Molecule for Mental Nourishment and More: Glucose Transporter Type 1—Biology and Deficiency Syndrome;Biomedicines;2022-05-26

2. Cancer Metabolism and Aggressive Tumor Behavior;Immuno-Oncology Crosstalk and Metabolism;2022

3. Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy;Cancer Drug Resistance;2021

4. Predicting tumor response and outcome of second-look surgery with 18F-FDG PET/CT: insights from the GINECO CHIVA phase II trial of neoadjuvant chemotherapy plus nintedanib in stage IIIc-IV FIGO ovarian cancer;European Journal of Nuclear Medicine and Molecular Imaging;2020-11-21

5. Cell Metabolism in Cancer: An Energetic Switch;Molecular and Cell Biology of Cancer;2019